Evotec is a drug manufacturers - specialty & generic business based in the US. Evotec shares (EVO) are listed on the NASDAQ and all prices are listed in US Dollars. Evotec employs 5,055 staff and has a trailing 12-month revenue of around $776.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.78 |
|---|---|
| 52-week range | $3.94 - $13.49 |
| 50-day moving average | $4.90 |
| 200-day moving average | $7.56 |
| Wall St. target price | $11.64 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.78 from 2024-07-23
| 1 week (2024-07-18) | 4.78 |
|---|---|
| 1 month (2024-06-25) | 1.27% |
| 3 months (2024-04-25) | -6.27% |
| 6 months (2024-01-25) | -38.95% |
| 1 year (2023-07-25) | -64.09% |
|---|---|
| 2 years (2022-07-25) | -63.73% |
| 3 years (2021-07-22) | 83.49 |
| 5 years (2019-07-24) | 58.88 |
Valuing Evotec stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evotec's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Evotec's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.4 million.
The EBITDA is a measure of a Evotec's overall financial performance and is widely used to measure a its profitability.
To put Evotec's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $776.6 million |
|---|---|
| Gross profit TTM | $151.5 million |
| Return on assets TTM | 0.03% |
| Return on equity TTM | -7.91% |
| Profit margin | -11.68% |
| Book value | $6.25 |
| Market Capitalization | $1.7 billion |
TTM: trailing 12 months
We're not expecting Evotec to pay a dividend over the next 12 months.
You may also wish to consider:
Evotec's shares were split on a 4:1 basis on 19 October 2021. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Evotec shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Evotec shares which in turn could have impacted Evotec's share price.
Over the last 12 months, Evotec's shares have ranged in value from as little as $3.94 up to $13.4924. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evotec's is 1.133. This would suggest that Evotec's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Evotec's beta into context you can compare it against those of similar companies.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc. ; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.